Immunovant, Inc. (IMVT): Price and Financial Metrics


Immunovant, Inc. (IMVT): $18.41

0.66 (+3.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMVT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMVT Stock Price Chart Interactive Chart >

Price chart for IMVT

IMVT Price/Volume Stats

Current price $18.41 52-week high $20.24
Prev. close $17.75 52-week low $3.14
Day low $17.33 Volume 1,159,458
Day high $18.52 Avg. volume 1,299,373
50-day MA $16.59 Dividend yield N/A
200-day MA $8.72 Market Cap 2.38B

Immunovant, Inc. (IMVT) Company Bio


Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.


IMVT Latest News Stream


Event/Time News Detail
Loading, please wait...

IMVT Latest Social Stream


Loading social stream, please wait...

View Full IMVT Social Stream

Latest IMVT News From Around the Web

Below are the latest news stories about IMMUNOVANT INC that investors may wish to consider to help them evaluate IMVT as an investment opportunity.

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in chronic inflammatory demyelinating polyneuropathy (CIDP) were initiated, as expectedPhase 3 clinical trial of batoclimab in myasthenia gravis (MG) is ongoing Cash balance of approximately $433 million as of December 31, 2022 NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a cl

Yahoo | February 3, 2023

The Quant Trading System Picking Stocks That Soar 300%

In the latter half of 2022, the S&P dropped 7%.

Luke Lango on InvestorPlace | January 18, 2023

Was anything negative for Immunovant Inc. (IMVT) stock last session?

The share price of Immunovant Inc. (NASDAQ:IMVT) fell to $18.06 per share on Tuesday from $18.60. While Immunovant Inc. has underperformed by -2.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IMVT rose by 147.40%, with highs and lows ranging from $20.24 to $3.14, whereas the […]

US Post News | January 18, 2023

Immunovant Stock: Initiating With A Buy Rating (NASDAQ:IMVT)

Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation. Read more to see the growth catalysts, risks and why I consider it a buy now.

Seeking Alpha | January 8, 2023

Is the Immunovant Inc. (NASDAQ:IMVT) stock an investment opportunity?

Immunovant Inc. (IMVT)’s stock is trading at $19.06 at the moment marking a rise of 3.08% from the last session close. As of this writing, shares are priced at -2.76% less than their 52-week high of $19.60, and 506.04% over their 52-week low of $3.14. Based on the past 30-day period, the stock price is […]

US Post News | January 5, 2023

Read More 'IMVT' Stories Here

IMVT Price Returns

1-mo -6.64%
3-mo 53.29%
6-mo 237.18%
1-year 211.51%
3-year 14.56%
5-year N/A
YTD 3.72%
2022 108.33%
2021 -81.55%
2020 191.05%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6375 seconds.